

RECEIVED
CENTRAL FAX CENTER

JAN 08 2007

Atty Docket No161 US UT01

FAX NO.: 571/273-8300

**OFFICIAL COMMUNICATION FOR THE ATTENTION OF
THE U.S. PATENT AND TRADEMARK OFFICE**

CERTIFICATION OF FACSIMILE TRANSMISSION


I hereby certify that the following documents in re Application of Landolfi et al., Application No. 10/774,076, filed February 6, 2004 for AMPHIREGULIN ANTIBODIES AND THEIR USE TO TREAT CANCER AND PSORIASIS are being facsimile transmitted to the United States Patent and Trademark Office, on the date shown below.

Documents Attached

1. Transmittal Form (1 page)
2. Amendment and Response (4 pages)

Number of pages being transmitted, including this page: 6

Dated: 8 January, 2007


Linda Pete

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (510) 574-1473*

PDL BIOPHARMA, INC.
Legal Department
34801 Campus Drive
Fremont, CA 94555
Telephone: 510/574-1400
Customer No.: 47470

JAN 08 2007

PTO/SB/21 (02-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/774,076
		Filing Date	February 6, 2004
		First Named Inventor	LANDOLFI, et. al
		Art Unit	1644
		Examiner Name	KIM, Yunsoo
Total Number of Pages in This Submission	5	Attorney Docket Number	161 US UT01

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 50-3270		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual name	Susan Harlocker, Reg. No. 59,144, PDL BioPharma, Inc.		
Signature	<i>Susan L Harlocker</i>		
Date	January 8, 2007		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO (Facsimile No. 571-273-8300) or deposited with the United States Postal Service with sufficient postage as Express mail (Label No.) in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 8, 2007.			
Typed or printed name	Linda Pete		
Signature	<i>Linda Pete</i>	Date	January 8, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED
CENTRAL FAX CENTER

JAN 08 2007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1644	:	
Examiner: Yunsoo Kim	:	
In re Application of:	:	AMPHIREGULIN ANTIBODIES
Nicholas Landolfi <i>et al.</i>	:	AND THEIR USE TO TREAT
	:	CANCER AND PSORIASIS
Serial No.: 10/774,076	:	
Filing Date: February 6, 2004	:	
Attorney Docket No.: 161 US UT01	:	
Customer No.: 47470	:	Confirmation No.: 7347

AMENDMENT AND RESPONSE

Fremont, CA 94555
January 8, 2007

Mail Stop: AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir or Madam:

This is a response to the final Office Action in the above-referenced application dated November 17, 2006, having a shortened statutory period set to expire February 17, 2007. Applicants are submitting this response within 2 months of the mailing date of the Action, thereby establishing a variable period for reply under MPEP §706.07(f). If any additional fees are required in order to maintain the pendency of this application, the Office is expressly authorized to charge such fees to Deposit Account No. 50-3270, referencing Attorney Docket No. 161 US UT01.